



11 August 2009
BioPharmica (ASX: BPH) ASX Announcement

US PATENT GRANTED FOR HLS5

BioPharmica Limited is pleased to announce that the patent "Tumour Suppressor Factor" No.7560253 has been issued as a patent in the United States. The HLS5 tumour suppressor gene was reported by Professor Klinken's team in 2004. In conjunction with BioPharmica the expert team at The West Australian Institute for Medical Research (WAIMR) led by Director Professor Peter Klinken are continuing with the research.

BioPharmica has developed an extensive patent portfolio and has exclusive rights to the tumor suppressor gene HLS5 both as a potential therapeutic target and also underpinning its involvement in a variety of disease pathways. The patent portfolio of technology surrounding HLS5 is currently going through National Phase filings in Australia, US and Europe. The Tumor Suppressor Gene HLS5 has a large amount of data gathered with the continued support of WAIMR.

Therapeutic Target

Tumour Suppressor Gene
Regulates transcription / signalling pathways

Anti-Cancer Therapy

Gene Therapy
Small molecules

Biomarker / Diagnostic Assays

Detect presence and severity of disease
Determine types of cancer and patients to target

Screening Assays / Research Tools

To find compounds for anti-cancer therapy
To determine MoA and relevance to disease

BioPharmica is seeking out-licensing or co-development opportunities with large pharma and biotech.

Yours sincerely,

David Breeze
Chairman

For more information contact:

Mr David Breeze
Chairman
BioPharmica Limited
Tel : +61 9 9328 8366